Sanofi (ETR:SNW)
Germany
· Delayed Price · Currency is EUR 104.14
+0.50 (0.48%)
Feb 21, 2025, 5:35 PM CET
Sanofi Revenue
In the year 2024, Sanofi had annual revenue of 44.29B EUR with 7.73% growth. Sanofi had revenue of 11.42B in the quarter ending December 31, 2024.
Revenue
44.29B
Revenue Growth
+7.73%
P/S Ratio
n/a
Revenue / Employee
534.35K
Employees
82,878
Market Cap
130.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 22.67B |
| Merck KGaA | 20.96B |
| Bayer Aktiengesellschaft | 46.74B |
| Fresenius SE & Co. KGaA | 22.81B |
| Sartorius Aktiengesellschaft | 3.38B |
| Fresenius Medical Care AG | 19.24B |
| Carl Zeiss Meditec AG | 2.08B |
| Fielmann Group AG | 2.16B |
Sanofi News
- 19 hours ago - Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease - GlobeNewsWire
- 2 days ago - Stocks to watch today on 21 Feb: Cipla, Senores, Narayana Hrudayalaya, Sanofi in pharmaceuticals and healthcare sector - Business Upturn
- 2 days ago - Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - Benzinga
- 3 days ago - Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth - Seeking Alpha
- 3 days ago - Sanofi to sell 50% stake in consumer health unit to CD&R - Seeking Alpha
- 3 days ago - Press Release: Sanofi and CD&R sign Opella share purchase agreement - GlobeNewsWire
- 4 days ago - Regeneron, Sanofi asthma therapy Dupixent under FDA review for rare skin condition - Seeking Alpha
- 8 days ago - Sanofi gets FDA approval for NovoLog insulin biosimilar - Seeking Alpha